Biosimilars Rheumatology Roundup for April 2023—Podcast Edition
On this episode of Not So Different, we recap some of the main news in April regarding biosimilars used to treat rheumatic conditions, including some progressions and some setbacks as well as research on nonmedical switching from originators to biosimilars.
FDA Issues Another CRL for Alvotech’s Adalimumab Biosimilar
Multiple Infliximab Biosimilar Switches Appear Safe, Effective for Patients With IBD
Study on Nonmedical Switching for Adalimumab Biosimilars Warns About Nocebo Effect
Spherix Global Insights: Despite High Awareness, Provider Comfort With Adalimumab Biosimilars Is Low
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
Study Reveals Factors That Dissuade Commercial Plans From Covering Biosimilars